J Rheum Dis.  2021 Apr;28(2):68-75. 10.4078/jrd.2021.28.2.68.

Health-related Quality of Life Outcomes of Adalimumab for Patients With Rheumatoid Arthritis in Korea

  • 1Department of Internal Medicine, Wonkwang University Hospital, Iksan, Korea
  • 2Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University School of Medicine, Guri, Korea
  • 3Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea
  • 4Department of Internal Medicine, Pohang St. Mary’s Hospital, Pohang, Korea
  • 5Department of Internal Medicine, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Suwon, Korea
  • 6Department of Internal Medicine, Eulji University Hospital, Eulji University School of Medicine, Daejeon, Korea
  • 7Department of Internal Medicine, Seoul Medical Center, Seoul, Korea
  • 8Department of Rheumatology, Ajou University School of Medicine, Suwon, Korea
  • 9Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea
  • 10AbbVie Ltd, Seoul, Korea
  • 11Department of Internal Medicine, Jeonbuk National University Medical School, Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical, Research Institute of Jeonbuk National University Hospital, Jeonju, Korea


Rheumatoid arthritis (RA) is a chronic, progressive, autoimmune disorder that impairs patients’ overall health-related quality of life (HRQOL). In this study, we evaluated the effect of adalimumab in Korean patients with active RA on HRQOL.
Patients included in the study had moderate to severe active RA that did not respond to conventional drugs with a Disease Activity Score of 28 joints >3.2 and were biologics-naïve. All patients received adalimumab 40 mg subcutaneously every other week and were followed for 24 weeks. The primary endpoint was the change in baseline Health Assessment Questionnaire Disability Index (HAQ-DI) score at week 24. Secondary endpoints were changes in the EuroQol 5-dimension 3-Level (EQ-5D-3L) baseline score and Short Form 36-Item Health Survey (SF-36) domain scores at weeks 12 and 24 and change in baseline HAQ-DI score at week 12.
In total, 91 Korean patients were included. Ninety-three percent of patients were in high disease activity with a baseline mean DAS28 value of 6.1 within all patients. The mean change from baseline in HAQ-DI scores were −0.46 at week 12 and∼0.67 at week 24 (p<0.0001). Additionally, EQ-5D-3L score at weeks 12 and 24 had significantly improved (p<0.0001) compared to baseline. SF-36 at weeks 12 and 24 had significantly improved (p<0.0001, p=0.0001) compared to baseline.
Treatment with adalimumab resulted in significant improvement in HAQ-DI, EQ-5D-3L, and SF-36 scores at 12 and 24 weeks in Korean RA patient.


Adalimumab; Patients; Quality of life; Rheumatoid arthritis; Antirheumatic agents
Full Text Links
  • JRD
export Copy
  • Twitter
  • Facebook
Similar articles
    DB Error: unknown error